Relugolix
Relugolix is an oral GnRH receptor antagonist that suppresses LH and FSH release, leading to reduced testosterone production. This mechanism is applied in research for hormone-dependent cancers like prostate cancer, utilizing both in vitro receptor binding assays and in vivo xenograft models to study its antineoplastic effects.
Product Specifications
CAS Number
737789-87-6
Product Name Alternative
Antagonistic, Inhibitor, GnRH Receptor, GnRH, GNRHR, GnRHR, GNRH Receptor, GNRHReceptor, Gonadotropin releasing hormone receptor, FSH, endometriosis, inhibit, prostate cancer, TAK 385, TAK385, TAK-385, RVT 601, RVT601, RVT-601, Relugolix, uterine fibroid
Field of Research
Pharmacology & Drug Discovery
Purity
98.64% (May vary between batches)
Solubility
DMSO:250 mg/mL (400.88 mM) ;10% DMSO+40% PEG300+5% Tween-80+45% Saline:1 mg/mL (1.6 mM)
Smiles
CONC (=O) Nc1ccc (cc1) -c1sc2n (Cc3c (F) cccc3F) c (=O) n (-c3ccc (OC) nn3) c (=O) c2c1CN (C) C
Molecular Formula
C29H27F2N7O5S
Molecular Weight
623.63
Storage Conditions
-20°C
Notes
For research use only.
Available Sizes
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
SIPA176Hu01-01 10 µg
Recombinant Tumor Necrosis Factor Receptor Superfamily, Member 17 (TNFRSF17)
Sign In for Pricing
View Details SIPA176Hu01-02 50 µg
Recombinant Tumor Necrosis Factor Receptor Superfamily, Member 17 (TNFRSF17)
Sign In for Pricing
View Details